PUBLICATIONS
"If it were not for the great variability among individuals
medicine might as well be a science and not an art."
Sir William Osler
Peer-Reviewed Articles
Exposure-efficacy meta-model of nintedanib in adult patients with chronic fibrosing interstitial lung diseases
Hartmann S, Janssen J, Ribbing J, Stowasser S, Korell J. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2025;early view. http://10.1002/psp4.70132
Population pharmacokinetics and exposure-response model-based Bayesian extrapolation of FVC-based efficacy endpoints from adults to pediatric patients receiving nintedanib
Hartmann S, Chan Kwong A, Ribbing J, Gahlemann M, Korell J. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2025;early view. http://10.1002/psp4.70135
Phase II randomized trial of BI 730357 for moderate-to-severe plaque psoriasis
Gooderham MJ, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow
H, Flack M, Korell J, Sofen H, Papp KA. Journal of Investigative Dermatology, 2025;145(8):1969-1978.e14. http://10.1016/j.jid.2024.12.025
Semi-mechanistic population pharmacokinetic modelling of DZIF-10c
Kurup S, de Mendizabal NV, Becker S, Bolella E, De Sousa D, Fätkenheuer G, Gruell H, Klein F, Malin JJ, Schmid U, Korell J. Journal of Pharmacokinetics and Pharmacodynamics, 2025;52(3). http://10.1007/s10928-024-09947-2
Less is more: Design considerations for interactive pharmacometrics tools - A case study using the Model Visualization Platform (MVP) app
Choy S, Kim JG, Korell J. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2025;14(5):819-821. http://10.1002/psp4.70023
Assessing drug-drug interaction and food effect for BCS Class 2 compound BI 730357 using a PBPK approach
Kanacher T, Sjögren E, Korell J, Plan E, Gomez-Mantilla JD, Ince I. Pharmaceutics, 2025;17(3):314. http://10.3390/pharmaceutics17030314
Bounded integer model-based analysis of psoriasis area and severity index
Ooi Q, Kristoffersson A, Korell J, Flack M, Plan E, Weber B. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2023;12:758-769. http://10.1002/psp4.12948
Parametric time-to-event model for acute exacerbations in idiopathic pulmonary fibrosis
Tang F, Weber B, Stowasser S, Korell J. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2020;9:87-95. http://10.1002/psp4.12485
Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine and quetiapine
Korell J, Green B, Rae A, Remmerie B, Vermeulen A. European Journal of Clinical Pharmacology, 2018;74(5):593-599. http://10.1007/s00228-018-2419-3
Determination of plasma concentration reference ranges for risperidone and paliperidone
Korell J, Green B, Remmerie B, Vermeulen A. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2017;6:589-595. http://10.1002/psp4.12217
Optimizing antipsychotic patient management using population pharmacokinetic models
Green B, Korell J, Remmerie B, Savitz A, Vermeulen A. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2017;6:573-575. http://10.1002/psp4.12212
A human challenge model for respiratory syncytial virus kinetics
Korell J, Green B, DeVincenzo J, Huntjens D. European Journal of Pharmaceutical Sciences, 2017;109(Suppl):S154-S160. http://10.1016/j.ejps.2017.05.070
A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials
Korell J, Martin SW, Karlsson MO, Ribbing J. Clinical Pharmacology & Therapeutics, 2016;99(3):315-324. http://10.1002/cpt.249
Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
Pan S, Korell J, Stamp LK, Duffull SB. European Journal of Clinical Pharmacology, 2015;71(12):1509-1516. http://10.1007/s00228-015-1951-7
Relationship between methotrexate polyglutamates and clinical response in RA
Pan S, Stamp LK, Duffull SB, Barclay ML, Dalrymple JM, Drake J, Zhang M, Korell J. Clinical Pharmacokinetics, 2014;53(12):1161-1170. http://10.1007/s40262-014-0179-5
Comparison of intracellular methotrexate kinetics
Korell J, Duffull SB, Dalrymple JM, Drake J, Zhang M, Barclay ML, Stamp LK. British Journal of Clinical Pharmacology, 2014;77(3):493-497. http://10.1111/bcp.12209
Parameterisation affects identifiability of population models
Shivva V, Korell J, Tucker IG, Duffull SB. Journal of Pharmacokinetics and Pharmacodynamics, 2014;41(1):81-86. http://10.1007/s10928-013-9347-8
Identifiability of population PK-PD models
Shivva V, Korell J, Tucker IG, Duffull SB. Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology, 2013;2:e49. http://10.1038/psp.2013.25
A semi-mechanistic red blood cell survival model
Korell J, Duffull SB. Journal of Pharmacokinetics and Pharmacodynamics, 2013;40(4):469-478. http://10.1007/s10928-013-9322-4
Population pharmacokinetic model for methotrexate in red blood cells
Korell J, Stamp LK, Barclay ML, Dalrymple JM, Drake J, Zhang M, Duffull SB. Clinical Pharmacokinetics, 2013;52(6):475-485. http://10.1007/s40262-013-0052-y
A pharmacokinetic model for the glycation of albumin
Alskär O, Korell J, Duffull SB. Journal of Pharmacokinetics and Pharmacodynamics, 2012;39(3):273-282. http://10.1007/s10928-012-9249-1
A statistical model for red blood cell survival time
Korell J, Coulter CV, Duffull SB. Journal of Theoretical Biology, 2011;268(1):39-49. http://10.1016/j.jtbi.2010.10.010
Evaluation of red blood cell labelling methods
Korell J, Coulter CV, Duffull SB. Journal of Theoretical Biology, 2011;291:88-98. http://10.1016/j.jtbi.2011.09.016
Modelling red blood cell survival data
Korell J, Vos FE, Coulter CV, Schollum JB, Walker RJ, Duffull SB. Journal of Pharmacokinetics and Pharmacodynamics, 2011;38(6):787-801. http://10.1007/s10928-011-9220-6
Oral Presentations
Pharmacometrics to inform clinical drug development
Korell J. 2nd Educational Pharmacometrics Summer Symposium, University of A Coruna, 2023, A Coruna, Spain.
Quantification of Dabigatran anticoagulation reversal: Bayesian analysis of the Idarucizumab-Dabigatran PK binding model
Korell J. ACoP 8, 2017, Fort Lauderdale, FL.
A population PKPD model for neutropenia during Hyper-CVAD chemotherapy in non-Hodgkin lymphoma
Sandhu G, Carrington C, Mapp S, Korell J. PAGANZ 17, 2015, Melbourne, Australia.
Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
Pan S, Korell J, Stamp LK, Duffull SB. PAGANZ 16, 2014, Dunedin, New Zealand.
Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in rheumatoid arthritis
Pan S, Stamp LK, Duffull SB, Korell J. ASCEPT New Zealand, 2014, Queenstown, New Zealand.
Extremes of body size in the dosing of high-dose methotrexate chemotherapy for non-Hodgkin lymphoma
Sandhu G, Carrington C, Mapp S, Hennig S, Korell J. ASCEPT, 2014, Melbourne, Australia.
Assessment of the activity of red blood cell methotrexate polyglutamates
Pan S, Korell J, Stamp LK, Duffull SB. ASCEPT New Zealand, 2013, Queenstown, New Zealand.
Identifiability of population pharmacokinetic-pharmacodynamic models
Shivva V, Korell J, Tucker IG, Duffull SB. PAGANZ 15, 2013, Brisbane, Australia.
Development of a simplified mathematical model of the human physiome – cardiovascular application
Korell J, Duffull SB. PAGANZ 15, 2013, Brisbane, Australia.
SimPharm v2.0: A patient-simulation based clinical pharmacology teaching tool for pharmacy students
Harper T, Korell J, Duffull SB. ASCEPT New Zealand, 2013, Queenstown, New Zealand.
Assessment of identifiability of pharmacokinetic models
Shivva V, Korell J, Tucker IG, Duffull SB. ASCEPT New Zealand, 2012, Queenstown, New Zealand.
Pharmacokinetics of methotrexate in red blood cells
Korell J, Stamp L, Duffull SB. ASCEPT New Zealand, 2012, Queenstown, New Zealand.
Development and application of a pharmacokinetic model for the glycation of albumin
Alskär O, Korell J, Duffull SB. PAGANZ 14, 2012, Melbourne, Australia.
Pharmacokinetics of methotrexate in red blood cells
Korell J, Stamp L, Duffull SB. PAGANZ 14, 2012, Melbourne, Australia.
Modelling red blood cell data
Korell J, Vos FE, Sanhajariya S, Coulter CV, Schollum JB, Walker RJ, Duffull SB. PAGANZ 13, 2011, Auckland, New Zealand.
Development and application of a pharmacokinetic model for the glycation of albumin
Alskär O, Korell J, Duffull SB. ASCEPT New Zealand, 2011, Christchurch, New Zealand.
Design of survival studies for red blood cells
Korell J, Coulter CV, Duffull SB. PAGANZ 12, 2010, Adelaide, Australia.
A statistical model for red blood cell survival time
Korell J, Coulter CV, Duffull SB. ASCEPT New Zealand, 2009, Dunedin, New Zealand.
Poster Presentations
Time-to-event model for acute exacerbations in idiopathic pulmonary fibrosis
Tang F, Weber B, Stowasser S, Korell J. ASCPT , 2019, Washington, DC.
Predicting mortality in idiopathic pulmonary fibrosis patients treated with nintedanib
Tang W, Menjoge S, Stowasser S, Korell J. ATS International Conference, 2018, San Diego, CA.
A population model for respiratory syncytial virus (RSV) kinetics using transit compartments based on human challenge data
Huntjens D, Korell J, Green B. ACoP 8, 2017, Fort Lauderdale, FL.
Development of an interactive tool to explore paediatric doses and sample size for paediatric trials
Cheng M, McDougall D, Korell J, Green B. WCoP, 2016, Brisbane, Australia.
Development and use of population reference ranges to interpret antipsychotic plasma concentrations
Vermeulen A, Remmerie B, Korell J, Green B, Savitz A. Society of Biological Psychiatry Annual Scientific Meeting, 2016, Atlanta, GA.
Predicting reductions in COPD exacerbations from FEV1 - A model-based meta-analysis
Ribbing J, Korell J, Cerasoli F, Milligan PA, Martin SW, Karlsson MO. ACoP 6, 2015, Washington, DC.
Extremes of body size in the dosing of high-dose methotrexate chemotherapy for non-Hodgkin lymphoma
Sandhu G, Carrington C, Mapp S, Hennig S, Korell J. ASCEPT, 2014, Melbourne, Australia.
Punching above the weight - high-dose methotrexate chemotherapy in extremes of body size
Sandhu G, Korell J, Mapp S, Carrington C. COSA Annual Scientific Meeting, 2014, Melbourne, Australia.
Effect of random non-compliance on plasma concentration targets - proof-of-concept analysis
Korell J, McLeay SC, Green B, Vermeulen A. ACoP 5, 2014, Las Vegas, NV.
Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
Pan S, Korell J, Stamp LK, Duffull SB. ACoP 5, 2014, Las Vegas, NV.
Relating intracellular methotrexate polyglutamate concentrations with clinical response in rheumatoid arthritis
Pan S, Korell J, Stamp LK, Duffull SB. PAGANZ 15, 2013, Brisbane, Australia.
Design of survival studies for red blood cells
Korell J, Coulter CV, Duffull SB. ASCEPT New Zealand, 2010, Christchurch, New Zealand.